INS and cystic fibrosis: The aim of this study was to test the hypothesis that treatment with Lumacaftor/Ivacaftor or Elexacaftor-Ivacaftor-Tezacaftor is associated with an improvement of the direct determinants of glucose regulation, i.e., β-cell function, insulin clearance and insulin sensitivity, in a cohort of children and young adults with CF.